Top Ten most popular articles on Pharmafile.com this week
September 8, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
This week saw a number of hard-hitting stories hit the headlines that are sure to have resonant consequences. Following the …
Aspirin may be a cost-effective alternative to fillings
September 8, 2017Medical Communications, Research and Development aspirin, biotech, dentist, drugs, pharma, pharmaceutical, tooth decay
Researchers from Queen University, Belfast, have discovered that aspirin may be able to reverse the effects of tooth decay. In …
Lily announces massive staff cuts of 3,500 to “streamline business”
September 8, 2017Manufacturing and Production, Medical Communications, Sales and Marketing
In a drastic bid to “streamline business, invest in new medicines and drive”, Eli Lilly has announced major staff cuts …
BMS’ Opdivo gets a potential first-line boost in kidney cancer
September 8, 2017Medical Communications, Research and Development Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has announced results from a Phase 3 trial showing that patients treated with Opdivo alongside Yervoy in patients …
Antidepressants polluting rivers building up in brains of fish
September 7, 2017Medical Communications antidepressants, biotech, drugs, pharma, pharmaceutical
A study of ecosystem of the Niagara River has discovered that antidepressants are building up in the brains of fish. …
Booklet labels or Just-In-Time labelling: A question of standards
September 7, 2017Business Services, Manufacturing and Production Faubel, Labelling, packaging
Pharmaceutical companies are multiplying their efforts to establish just-in-time labeling. For Anthony Morrow, Business Development Manager Northern Europe at Faubel, …
High demands: Requirements on the labelling of pharmaceutical products are growing continuously
September 7, 2017Business Services, Manufacturing and Production Faubel, Labelling
There are numerous criteria to be met by label manufacturers. In this context, topics such as patient compliance and smart …
Vertex Pharma bring in new CFO, shares rise
September 7, 2017Ironwood Pharmaceuticals, Vertex pharmaceuticals, biotech, drugs, pharma, pharmaceutical
Vertex Pharmaceuticals announced the appointment of J&J veteran, Tom Graney, as Senior Vice President and Chief Financial Officer. Graney will …
Spotting Leukaemia
September 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, leukaemia, pharma, pharmaceutical
Leukaemia is a household name, but how much do we really understand about it? Not enough, says Bethany Torr, Campaigns …
New ‘pen’ device identifies cancerous tissue in just ten seconds
September 7, 2017Research and Development Cancer, University of Texas, digital, medicine, pharma, pharmaceutical, tumour
Scientists at the Baylor College of Medicine, University of Texas have developed a device which they claim can identify cancerous …
BMS hit by clinical trial hold from FDA
September 7, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical
The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …
Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%
September 7, 2017Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …
MSD plays catch up with €464m deal for fledgling biotech
September 7, 2017Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical
MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
FDA halts trial after first CAR T-associated patient death
September 6, 2017Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical
French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …
Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million
September 6, 2017Research and Development, Sales and Marketing FDA, Novo Nordisk, US, US Justice Department, Victoza, diabetes, pharma, pharmaceutical
Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …
Anti-HIV drug PrEP proves safety in gay and bisexual adolescents
September 6, 2017Research and Development Gilead, HIV, Pharamceuticals, PrEP, Truvada, health, medicine, pharma
A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …
Real-world data prove efficacy of Eisai and Bial’s epilepsy treatment
September 6, 2017Research and Development Bial, Eisai, Zebinix, epilepsy, pharma
Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset …
Novartis exec designated as new CEO after Jimenez announces retirement
September 5, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, a, joe jimenez, phar, pharma, pharmaceuticals
Novartis has announced that its Chief Executive, Joe Jimenez, is set to retire next year. In his place, Vasant Narasimhan …
Takeda’s Ninlaro knocked back by NICE for second time
September 5, 2017Research and Development, Sales and Marketing Ninlaro, Takeda, biotech, drugs, pharma, pharmaceutical
NICE has revealed that the outcome of its consultation process for Ninlaro (ixazomib), Takeda’s treatment for relapsed or refractory multiple …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
